KR920700227A - 초고활성 인체 인슐린 동족체 - Google Patents

초고활성 인체 인슐린 동족체

Info

Publication number
KR920700227A
KR920700227A KR1019890700480A KR890700480A KR920700227A KR 920700227 A KR920700227 A KR 920700227A KR 1019890700480 A KR1019890700480 A KR 1019890700480A KR 890700480 A KR890700480 A KR 890700480A KR 920700227 A KR920700227 A KR 920700227A
Authority
KR
South Korea
Prior art keywords
composition
insulin
human insulin
active
homologue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890700480A
Other languages
English (en)
Other versions
KR970009353B1 (ko
Inventor
지. 캇소야니스 파나요티스
피. 슈바르쯔 제랄드
Original Assignee
원본미기재
마운트 시나이 스쿨 오브 메디신 오브 더 시티 유니버시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 마운트 시나이 스쿨 오브 메디신 오브 더 시티 유니버시티 오브 뉴욕 filed Critical 원본미기재
Publication of KR920700227A publication Critical patent/KR920700227A/ko
Application granted granted Critical
Publication of KR970009353B1 publication Critical patent/KR970009353B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

초고활성 인체 인슐린 동족체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 CM－셀룰로오스 컬럼으로부터의 조(祖) 인체〔10－아스파르트산〕B 사슬 S－술포네이트의 용리를 나타내는 크로마토그램 도면임,
제2도는 인체 A 사슬 S－술포네이트와 인체〔10－아스파르트산〕B 사슬 S－술포네이트의 배합 혼합물의 용리를 나타낸 HPLC 크로마토그램 도면임,
제3도는〔10－아스파르트산－B〕인체 인슐린(o)과 소의 인슐린(o)에 의한 125I－인슐린의 쥐의 간 플라스마 인슐린 섭수체에의 결합의 경쟁적 저해를 나타낸 그래프임.

Claims (15)

  1. 다음의 구조식을 갖는 초고활성 인슐린 동족체
  2. 다음의 구조식을 갖는 초고활성 인슐린 동족체
  3. 다음의 구조식을 갖는 초고활성 인슐린 동족체
  4. 다음의 일반식을 갖는 초고활성 인슐린 동족체
    상기 일반식에서, X는 α－아미노－아디프산 또는 고급 동족체임.
  5. 〔10－아스파르트산－B〕인체 인슐린, 데스－펜타펩티드(B26－B30)－〔카르복사미드〕인체 인슐린 및 데스－펜타펩티드(B26－B30)－〔카르복사미드〕인체 인슐린 중에서 선택한 초고활성 인체 인슐린 동족체의 치료적 유효량과 약리적으로 허용되는 담체로 이루어짐을 특징으로하는 당뇨병 치료제 조성물.
  6. 제5항에 있어서, 상기 조성물이 근육내 투여용인 것이 특징인 당뇨병 치료제 조성물.
  7. 제5항에 있어서, 상기 조성물이 피하투여용인 것이 특징인 당뇨병 치료제 조성물.
  8. 제5항에 있어서, 상기 조성물이 정맥내 투여용인 것이 특징인 당뇨병 치료제 조성물.
  9. 제5항에 있어서, 상기 조성물이 이식가능한 펌프에 의한 투여용인 것이 특징인 당뇨병 치료제 조성물.
  10. 제5항에 있어서, 비강 분무 투여용인 것이 특징인 당뇨병 치료제 조성물.
  11. 〔10－아스파르트산－B〕인체 인슐린, 데스－펜타펩티드(B26－B30)－〔카르복사미드〕인체 인슐린 및 데스－펜타펩티드(B26－B30)－〔카르복사미드〕인체 인슐린 중에서 선택한 초고활성 인체 인슐린 동족체의 치료적 유효량과 약리적으로 허용되는 담체를 투여하는 것으로 된 당뇨병 치료법.
  12. 제11항에 있어서, 초고활성 인슐린 동족체를 근육내로 투여함을 특징으로하는 당뇨병 치료법.
  13. 제11항에 있어서, 초고활성 인슐린 동족체를 피하투여함을 특징으로하는 당뇨병 치료법.
  14. 제11항에 있어서, 초고활성 인슐린 동족체를 정맥내로 투여함을 특징으로하는 당뇨병 치료법.
  15. 제11항에 있어서, 초고활성 인슐린 동족체를 이식가능한 펌프에 의해 투여함을 특징으로하는 당뇨병 치료법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890700480A 1987-07-17 1988-07-07 초고활성 인체 인슐린 동족체 Expired - Fee Related KR970009353B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US074,558 1987-07-17
US07/074,558 US4992418A (en) 1987-07-17 1987-07-17 Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
PCT/US1988/002289 WO1989000580A1 (en) 1987-07-17 1988-07-07 Superactive human insulin analogues

Publications (2)

Publication Number Publication Date
KR920700227A true KR920700227A (ko) 1992-02-19
KR970009353B1 KR970009353B1 (ko) 1997-06-10

Family

ID=22120214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890700480A Expired - Fee Related KR970009353B1 (ko) 1987-07-17 1988-07-07 초고활성 인체 인슐린 동족체

Country Status (10)

Country Link
US (1) US4992418A (ko)
EP (1) EP0382732B1 (ko)
JP (1) JP2729498B2 (ko)
KR (1) KR970009353B1 (ko)
AU (1) AU616131B2 (ko)
DE (1) DE3887338T2 (ko)
DK (1) DK13990A (ko)
FI (1) FI98731C (ko)
HU (1) HU205145B (ko)
WO (1) WO1989000580A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE101620T1 (de) * 1988-06-23 1994-03-15 Hoechst Ag Mini-proinsulin, seine herstellung und verwendung.
US5656590A (en) * 1991-05-24 1997-08-12 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
IL102240A0 (en) * 1991-06-21 1993-01-14 Lilly Co Eli Insulin analogs
TW224471B (ko) * 1991-11-26 1994-06-01 Lilly Co Eli
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1458240B1 (en) * 2001-06-08 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
JP2014533241A (ja) * 2011-10-27 2014-12-11 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 超濃縮速効型インスリン類似体製剤
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3420810A (en) * 1966-10-25 1969-01-07 Atomic Energy Commission Process for joining the a and b chains of insulin
DE2252157C3 (de) * 1972-10-25 1976-03-18 Hoechst Ag Zwischenprodukte zur herstellung von insulin, insulin-analogen und -derivaten und verfahren zur herstellung von insulin, insulin analogen und derivaten
DE2253327A1 (de) * 1972-10-31 1974-05-09 Hoechst Ag Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
DD153829A1 (de) * 1979-08-09 1982-02-03 Guenter Losse Verfahren zur herstellung neuartiger hybridinsuline mit insulinaehnlicher wirkung
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4430266A (en) * 1980-11-28 1984-02-07 Eli Lilly And Company Process for producing an insulin precursor
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US4459226A (en) * 1982-02-26 1984-07-10 Eli Lilly And Company Process for recovering insulin
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4569791A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation

Also Published As

Publication number Publication date
HUT54178A (en) 1991-01-28
DE3887338T2 (de) 1994-05-05
EP0382732B1 (en) 1994-01-19
FI98731C (fi) 1997-08-11
AU616131B2 (en) 1991-10-17
AU2126988A (en) 1989-02-13
DE3887338D1 (de) 1994-03-03
FI98731B (fi) 1997-04-30
US4992418A (en) 1991-02-12
DK13990D0 (da) 1990-01-17
JP2729498B2 (ja) 1998-03-18
DK13990A (da) 1990-01-17
EP0382732A1 (en) 1990-08-22
HU205145B (en) 1992-03-30
KR970009353B1 (ko) 1997-06-10
JPH02504274A (ja) 1990-12-06
FI900249A0 (fi) 1990-01-16
WO1989000580A1 (en) 1989-01-26

Similar Documents

Publication Publication Date Title
Nauck et al. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
KR920700227A (ko) 초고활성 인체 인슐린 동족체
US6063761A (en) Hepatoselective pharmaceutical actives
KR0131087B1 (ko) 인슐린 유사성 성장인자 i을 함유하는 약제학적 제제
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
IL208184A0 (en) Glp-1, and methods for treating diabetes
JP2003520822A5 (ko)
KR920700226A (ko) 선형 소마토스타틴 유사체
US4652548A (en) Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
SE9702401D0 (sv) Pharmaceutical use
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
US4652547A (en) Pharmaceutical formulations comprising human insulin and human proinsulin
Wilson et al. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor
TJ286B (en) A method for treatment or prevention of obesity
Chodoroff et al. Cheiralgia paresthetica and linear atrophy as a complication of local steroid injection
RU96115219A (ru) Способ лечения больных сахарным диабетом
Sassolas et al. Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men
Bondesen et al. Plasma secretin in response to pure bile salts and endogenous bile in man
EP0213676B1 (en) Pharmaceutical compositions containing acth (1-24) for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
Izukura et al. Intracolonic infusion of bile salt stimulates release of peptide YY and inhibits cholecystokinin-stimulated pancreatic exocrine secretion in conscious dogs
Knudtzon Acute in-vivo effects of adrenocorticotrophin on plasma levels of glucagon, insulin, glucose and free fatty acids in rabbits: involvement of the alpha-adrenergic nervous system
Pramming et al. Diabetes Unit, Freeman Hospital
Lien et al. Prolonged suppression of pituitary and pancreatic hormone release by a somatostatin analog
JPS6237017B2 (ko)
HK1006283B (en) Pharmaceutical compositions containing acth fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20001025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20001025